Mumbai, June 16 -- The stock has gained 6.01% over four sessions, 24.09% in the past three months and 10.24% so far in 2026.

Investor sentiment remained positive after the diagnostics company announced on 12 June that it had incorporated a wholly owned subsidiary, DR LAL PATHLABS FZCO, in Dubai, United Arab Emirates.

The new entity has been established in the Dubai Multi Commodities Centre (DMCC) and will focus on strategic investments in diagnostics and allied healthcare activities. The company said the subsidiary will explore potential acquisitions, partnerships and joint ventures in the sector.

Dr Lal PathLabs has subscribed to the entire share capital of the subsidiary amounting to AED 19.135 million, divided into 19,135 shares of ...